URIHK

Universal Regeneration (URIHK) is a Hong Kong-based biotechnology company specializing in regenerative medicine through in vivo cell transdifferentiation. The company utilizes proprietary small molecule cocktails to reprogram existing cells within the body—such as myofibroblasts—into functional cells like hepatocytes or renal tubular cells to restore organ function. Their primary focus is on treating chronic and end-stage organ diseases, including chronic kidney disease and liver fibrosis, where traditional treatments are limited. By avoiding the complexities of cell transplantation and ex vivo manipulation, URIHK aims to provide a more accessible and scalable approach to organ repair. The company is currently in the pre-clinical stage with a pipeline of candidates targeting nephrology, hepatology, and endocrinology. URIHK is supported by leading venture capital firms and is a prominent member of the Hong Kong Science Park biotech ecosystem.